A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON*S DISEASE

Published: 16-11-2021
Last updated: 05-04-2024

The objective of the study is to assess the safety and tolerability, and to characterize the pharmacokinetics (PK) and pharmacodynamics (e.g., Cerebrospinal fluid [CSF] levels of IL-1β, TSPO positron emission tomography [PET] imaging) of...

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Neurological disorders NEC
Study type	Interventional

Summary

ID

NL-OMON54457

Source
ToetsingOnline

Brief title
BP43176 IZD334

Condition

- Neurological disorders NEC

Synonym
EARLY IDIOPATHIC PARKINSON□S DISEASE, Parkinson's disease

Research involving
Human

Sponsors and support

Primary sponsor: Roche Nederland B.V.
Source(s) of monetary or material Support: Roche Nederland B.V.

Intervention

Keyword: Parkinson's disease, phase 1b, selnoflast

Outcome measures

Primary outcome

To evaluate the safety and tolerability of selnoflast compared to placebo.

Secondary outcome

To investigate the pharmacokinetics of selnoflast (and metabolites, as

appropriate) in plasma.

To evaluate the effect of selnoflast on neuroinflammation in brain areas as

measured by TSPO-PET [18F]-DPA-714 imaging binding.

Study description

Background summary

PD is a progressive and incurable neurodegenerative disorder affecting more than 10 million people worldwide (Parkinson*s Disease Foundation 2019). Age is the main risk factor for PD and this prevalence is estimated to drastically increase in the next decades, partially due to a global rise in average life expectancy. The etiology of PD is unknown, and the incidence seems to vary within subgroups defined by ethnicity, genotype, or environment (Poewe et al. 2017). PD is characterized by a progressive neurodegeneration of the central and peripheral nervous systems, with typical neuropathological features. Growing evidence suggests that the NLRP3 inflammasome and microglial activation

may play a role in PD by promoting neuronal dysfunction and neurodegeneration

Study objective

The objective of the study is to assess the safety and tolerability, and to characterize the pharmacokinetics (PK) and pharmacodynamics (e.g., Cerebrospinal fluid [CSF] levels of IL-1β, TSPO positron emission tomography [PET] imaging) of selnoflast administered orally to participants with early PD.

Study design

A Phase 1b, Adaptive, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel Design Study.
The trial will compare daily administrations of selnoflast with matching placebo in participants with early PD.

Intervention

A minimum of 48 eligible participants will be randomized to either receive selnoflast 200 mg BID or placebo in a double-blind manner in a ratio active/placebo of 2:1.
Treatment duration will be approximately 28 days for all participants. After the last dose of selnoflast or placebo, all participants will enter a safety follow-up period for 14 days.

Study burden and risks

Subject undergoes a 4-week treatment period in which they have to take medication or placebo 2x daily and keep this in a diary.
In total, the subjects will make approximately 11 visits to the research center. Of which 2 will be at the central imaging center in Amsterdam.
The investigational product may cause side effects as described in the PIS.
Blood is also drawn at most visits. The following invasive procedures will also be performed: Insertion of an arterial line for blood collection during TSPO-PET (2x), DAT-Scan (1x), lumbar puncture (2x), MRI (1x)

Contacts

Public
Roche Nederland B.V.

Beneluxlaan 2a
Woerden 3446 GR
NL

Scientific
Roche Nederland B.V.

Beneluxlaan 2a
Woerden 3446 GR
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

*Age 40-85 years
*Diagnosis of clinically probable idiopathic PD based on MDS criteria with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity)
*A time from diagnosis of PD of at least 3 to maximum 60 months at screening

Other inclusion criteria can be found in protocol section 5.1

Exclusion criteria

*Medical history indicating a Parkinsonian syndrome other than idiopathic PD
*History of brain surgery for PD.
*Known carriers for mutations in the following genes: alpha-synuclein, LRRK2, GBA, PRKN, PINK1, or DJ1.
*Diagnosis of dementia or another significant central nervous system (CNS) disease other than PD; history of repeated clinically significant head injury as judged by the Investigator; history of epilepsy or seizure disorder other than febrile seizures as a child.

Other inclusion criteria can be found in protocol section 5.2

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	14-09-2022
Enrollment:	32
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Selnoflast
Generic name:	Selnoflast

Ethics review

Approved WMO Date:	16-11-2021
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	12-05-2022
Application type:	First submission

Review commission:	METC Amsterdam UMC
Approved WMO Date:	04-07-2022
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	10-10-2022
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	13-05-2023
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO Date:	05-07-2023
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2021-002345-15-NL
CCMO	NL78759.029.21